FibroGen, Inc.

Equities

FGEN

US31572Q8087

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 20:34:28 18/07/2024 BST 5-day change 1st Jan Change
1.035 USD -3.27% Intraday chart for FibroGen, Inc. +6.20% +17.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell Small Cap Comp Value Index CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell Small Cap Completeness Index CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Value Index CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 2000 Index CI
FibroGen, Inc.(NasdaqGS:FGEN) added to Russell Microcap Index CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 2500 Value Index CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 2000 Value Index CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 2000 Dynamic Index CI
FibroGen, Inc.(NasdaqGS:FGEN) added to Russell Microcap Value Index CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 2500 Index CI
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index CI
Transcript : FibroGen, Inc. - Special Call
Transcript : FibroGen, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:00 AM
Top Premarket Gainers MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier MT
FibroGen To Begin Trials on Tumor Treatment After FDA OK DJ
FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors CI
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting CI
Top Premarket Gainers MT
Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024
Earnings Flash (FGEN) FIBROGEN Posts Q1 Revenue $55.9M, vs. Street Est of $36.4M MT
FibroGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting CI
Faron Pharmaceuticals reappoints former finance chief on interim basis AN
Top Midday Decliners MT
Chart FibroGen, Inc.
More charts
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
1.07 USD
Average target price
1.75 USD
Spread / Average Target
+63.55%
Consensus
  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. News FibroGen, Inc.
  5. FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier